• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by BioAge Labs Inc.

    3/20/25 5:23:19 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOA alert in real time by email
    S-8 1 bioa-s8-march2025-new.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 20, 2025

    Registration No. 333-[xxxx]

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE

    SECURITIES ACT OF 1933

    BIOAGE LABS, INC.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware

    47-4721157

    (State or other jurisdiction of

    (I.R.S. Employer

    incorporation or organization)

    Identification Number)

    1445A South 50th Street

    Richmond, California 94804

    (510) 806-1445

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

    2024 Equity Incentive Plan

    2024 Employee Stock Purchase Plan

    (Full title of the plans)

    Kristen Fortney, Ph.D.

    Chief Executive Officer and President

    BioAge Labs, Inc.

    1445A South 50th Street

    Richmond, California 94804

    (510) 806-1445

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Please send copies of all communications to:

    Matthew Rossiter, Esq.

    Robert A. Freedman, Esq.

     


     

    Julia Forbess, Esq.

    Fenwick & West LLP

    555 California Street, 12th Floor

    San Francisco, California 94104

    (415) 875-2300

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E of Form S-8, BioAge Labs, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) to register (a) 1,792,501 additional shares of the Registrant’s common stock, par value $0.00001 per share (“common stock”) under the Registrant’s 2024 Equity Incentive Plan and (b) 358,500 additional shares of the Registrant’s common stock under the Registrant’s 2024 Employee Stock Purchase Plan, pursuant to the provisions in those plans providing for an automatic annual increase in the number of shares reserved for issuance under such plans on January 1, 2025. This Registration Statement hereby incorporates by reference the contents of the Registrant’s previous registration statement on Form S-8 filed with the Commission on September 26, 2024 (Registration No. 333-282352) to the extent not superseded hereby.

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for by Part I of Form S-8 is omitted from this Registration Statement and has been or will be sent or given to participating service providers in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:

    (a)
    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 20, 2025, pursuant to Section 13(a) of the Exchange Act;
    (b)
    All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrants Annual Report on Form 10-K referred to in (a) above; and
    (c)
    The description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A (File No. 001-42279) filed on September 18, 2024 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to documents or information deemed to have been furnished an note filed in accordance with the rules of the Commission. Unless expressly incorporated into this Registration Statement, a report deemed to be furnished but not filed on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

     

     


     

    Item 5. Interests of Named Experts and Counsel

     

    As of the date of this registration statement, individuals and entities associated with Fenwick & West LLP beneficially own an aggregate of 16,653 shares of the Registrant’s common stock.

     

     

    Item 8. Exhibits

     

    The following exhibits are filed herewith:

     

    Exhibit

    Incorporated by Reference

    Number

    Exhibit Description

    Form

    File No.

    Exhibit

    Filing Date

    Filed Herewith

    3.1

    Restated Certificate of Incorporation of the Registrant

    10-Q

    001-42279

    3.1

    11/7/2024

    3.2

    Amended and Restated Bylaws of the Registrant

    10-Q

    001-42279

    3.2

    11/7/2024

    4.1

    Form of Common Stock Certificate

    S-1/A

    333-281901

    4.1

    09/03/2024

    5.1

    Opinion of Fenwick & West LLP

    X

    23.1

    Consent of Fenwick & West LLP (contained in Exhibit 5.1)

    X

    23.2

    Consent of KPMG LLP

    X

    24.1

    Power of Attorney (included on the signature page to this Registration Statement)

    X

    99.1

    2024 Equity Incentive Plan, and forms of award agreements thereunder

    10-K

    001-42279

    10.2

    03/20/2025

     

    99.2

    2024 Employee Stock Purchase Plan, and forms of award agreements thereunder

    S-1/A

    33-281901

    10.4

    09/18/2024

    107

    Fee Table

    X

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Richmond, State of California, on this 20th day of March, 2025.

     

     

     

    BIOAGE LABS, INC.

     

     

    By:

    /s/ Kristen Fortney, Ph.D.

     

    Kristen Fortney, Ph.D.

     

    Chief Executive Officer and President

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kristen Fortney, Ph.D. and Dov Goldstein, M.D., and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the date indicated.

     

     

     

     

     

    Name

    Title

    Date

    /s/ Kristen Fortney

    Kristen Fortney, Ph.D.

    Chief Executive Officer, President and Director

    (Principal Executive Officer)

    March 20, 2025

     

     

     

    /s/ Dov Goldstein

    Dov Goldstein, M.D.

    Chief Financial Officer

    (Principal Financial Officer)

    March 20, 2025

     

     

     

    /s/ Shane Barton

    Shane Barton

    Senior Vice President of Finance

    (Principal Accounting Officer)

    March 20, 2025

     

     

     

    /s/ Jean-Pierre Garnier

    Jean-Pierre Garnier, Ph.D.

    Chair of the Board of Directors

    March 20, 2025

     

     

     

    /s/ Michael Davidson

    Michael Davidson, M.D.

    Director

    March 20, 2025

     

     

     

    /s/ Patrick Enright

    Patrick Enright

    Director

    March 20, 2025

     

     

     

    /s/ James Healy

    James Healy, M.D., Ph.D.

    Director

    March 20, 2025

     

     


     

     

     

     

     

     

     

     

     

     

    /s/ Rekha Hemrajani

    Rekha Hemrajani

    Director

    March 20, 2025

     

     

     

    /s/ Eric Morgen

    Eric Morgen, M.D.

    Director

    March 20, 2025

     

     

     

    /s/ Vijay Pande

    Vijay Pande, Ph.D.

    Director

    March 20, 2025

     

     


    Get the next $BIOA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOA

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    12/10/2024$40.00 → $5.00Overweight → Underweight
    Morgan Stanley
    12/9/2024$42.00 → $7.00Buy → Hold
    Jefferies
    12/9/2024$45.00 → $7.00Buy → Neutral
    Citigroup
    10/21/2024$45.00Buy
    Citigroup
    10/21/2024$42.00Buy
    Jefferies
    10/21/2024$40.00Overweight
    Morgan Stanley
    More analyst ratings

    $BIOA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on BioAge Labs

      William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform

      2/28/25 7:20:24 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously

      12/10/24 7:54:08 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs downgraded by Jefferies with a new price target

      Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously

      12/9/24 7:29:20 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:11:28 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:10:37 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Chief Operating Officer Morgen Eric

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      2/25/25 4:28:11 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioAge Labs Inc.

      10-Q - BioAge Labs, Inc. (0001709941) (Filer)

      5/6/25 4:40:22 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BioAge Labs, Inc. (0001709941) (Filer)

      5/6/25 4:35:09 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by BioAge Labs Inc.

      DEFA14A - BioAge Labs, Inc. (0001709941) (Filer)

      4/17/25 4:10:03 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioAge Labs Inc.

      SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

      11/14/24 4:15:56 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BioAge Labs Inc.

      SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

      11/12/24 4:15:53 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by BioAge Labs Inc.

      SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

      10/4/24 8:21:35 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BIOA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

      Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR&D expands therapeutic approach to novel metabolic aging targetsProgression of preclinical next-generation APJ agonists for obesity RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its first quarter 2025 financial results. "The first quarter of 2025 was marke

      5/6/25 4:30:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

      Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended Decembe

      3/20/25 4:30:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioArctic receives Orphan Drug Designation for exidavnemab the US

      STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need. Multiple System Atrophy (MSA) is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is characterized by pathological alpha-synuclein aggregation, that causes gradual damage to nerve cells in the brain. This affects balance, movement and the autonomic nervous system, which

      3/17/25 1:49:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:11:28 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:10:37 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      10/3/24 7:19:49 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care